NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT01746225 2023-06-01
SNAP
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03567720 2023-06-01
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
Phase 2 Unknown
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT02106884 2019-11-06
QOLINPAC
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT02076243 2017-10-25
Treatment With Nab-paclitaxel in Cutaneous SCC
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00093119 2017-04-26
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Celgene
Phase 2 Completed
NCT01964534 2017-01-31
AFUGEM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT00046514 2016-12-15
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
Celgene Corporation
Phase 2 Completed
NCT00607438 2012-05-11
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Veeda Oncology
Phase 2 Terminated